Literature DB >> 18190824

Salvage surgery for locally recurrent prostate cancer after radiation therapy: tricks of the trade.

Dan Leibovici1, Philippe E Spiess, Lior Heller, Miguel Rodriguez-Bigas, George Chang, Louis L Pisters.   

Abstract

Biochemical recurrence after either radical prostatectomy or radiation therapy of prostate cancer will develop in an estimated 50,000 U.S. men. Salvage therapy has the potential of curing an isolated local recurrence of prostate cancer, however, this comes at the cost of potential morbidity. Salvage surgery after primary radiotherapy is technically demanding, and surgical expertise is necessary to optimize treatment outcomes while minimizing the inherent risks of the operation. Over the last decade, we have developed a substantial experience in salvage surgery for locally recurrent prostate cancer, and have developed key technical points and innovations that include primary closure of the bladder neck, bladder augmentation, and catheterizable urinary reconstruction using a Monti or Mitrofanoff procedure as a method of reducing the risks of postoperative urinary incontinence. We hope this review will provide the surgical oncologist and urologist with the important considerations that must be considered in salvage surgery. In addition, we discuss the importance and surgical details of using a well-vascularized rectus flap as a method of reducing perioperative morbidity.

Entities:  

Mesh:

Year:  2007        PMID: 18190824     DOI: 10.1016/j.urolonc.2006.12.016

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  7 in total

Review 1.  Re-irradiation for salvage of prostate cancer failures after primary radiotherapy.

Authors:  Stephen J Ramey; David T Marshall
Journal:  World J Urol       Date:  2012-09-28       Impact factor: 4.226

2.  Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.

Authors:  Daher C Chade; Shahrokh F Shariat; Angel M Cronin; Caroline J Savage; R Jeffrey Karnes; Michael L Blute; Alberto Briganti; Francesco Montorsi; Henk G van der Poel; Hendrik Van Poppel; Steven Joniau; Guilherme Godoy; Antonio Hurtado-Coll; Martin E Gleave; Marcos Dall'Oglio; Miguel Srougi; Peter T Scardino; James A Eastham
Journal:  Eur Urol       Date:  2011-03-21       Impact factor: 20.096

3.  Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy.

Authors:  Lino M Sawicki; Julian Kirchner; Carolin Buddensieck; Christina Antke; Tim Ullrich; Lars Schimmöller; Johannes Boos; Christoph Schleich; Benedikt M Schaarschmidt; Christian Buchbender; Philipp Heusch; Robert Rabenalt; Peter Albers; Gerald Antoch; Hans-Wilhelm Müller; Hubertus Hautzel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-03-16       Impact factor: 9.236

4.  [Brachytherapy of the prostate cancer].

Authors:  S H Stübinger; R Wilhelm; S Kaufmann; M Döring; S Hautmann; K P Jünemann; R Galalae
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639

Review 5.  Salvage therapy for prostate cancer recurrence after radiation therapy.

Authors:  Jared M Cox; J Erik Busby
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

6.  Early prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral texture.

Authors:  Ali Sadeghi-Naini; Lakshmanan Sannachi; Kathleen Pritchard; Maureen Trudeau; Sonal Gandhi; Frances C Wright; Judit Zubovits; Martin J Yaffe; Michael C Kolios; Gregory J Czarnota
Journal:  Oncotarget       Date:  2014-06-15

7.  Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer.

Authors:  Constantinos Zamboglou; Hans-Christian Rischke; Philipp Tobias Meyer; Sven Knobe; Natalja Volgeova-Neher; Michael Kollefrath; Cordula Annette Jilg; Anca Ligia Grosu; Dimos Baltas; Malte Kroenig
Journal:  J Contemp Brachytherapy       Date:  2016-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.